This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Can Hospital-Products Unit Aid Baxter (BAX) in Q1 Earnings?
by Zacks Equity Research
Positive tidings on regulatory front, expanding Hospital-Products portfolio, strategic collaborations and strong presence in the international markets are key positives for Baxter's (BAX) Q1 results.
3 Stocks to Buy Ahead of Earnings
by Benjamin Rains
Stocks opened higher on Monday as investors seem to think the U.S.-led air strikes on Syria won't lead to a much larger conflict. The strikes also coincided with the real start of first quarter earnings season, which investors should use as a way to fight off the volatility that has plagued markets recently.
Will Core Segmental Growth Aid Stryker (SYK) in Q1 Earnings?
by Zacks Equity Research
Stryker's (SYK) acquisition-driven strategy is likely to boost Q1 results through the expansion of product offerings.
Can Instruments Drive Intuitive Surgical (ISRG) Q1 Earnings?
by Zacks Equity Research
Intuitive Surgical's (ISRG) developments on the da Vinci platform are a positive, while intense competition raises concern.
Can Solid Medical Devices Drive Abbott's (ABT) Q1 Earnings?
by Zacks Equity Research
Abbott (ABT) poised to gain on continued growth in Medical devices business in Q1.
Can Solid EPD Business Drive Abbott's (ABT) Q1 Earnings?
by Zacks Equity Research
Abbott (ABT) poised to ride high on strength in EPD business in Q1.
Can Steady Overall Growth Drive Abbott's (ABT) Q1 Earnings?
by Zacks Equity Research
Abbott (ABT) to see impressive year-over-year rise in revenues on strength in all business segments in Q1.
Will Buyouts Help Quest Diagnostics (DGX) Beat Q1 Earnings?
by Zacks Equity Research
Quest Diagnostics' (DGX) successful strategies to build esoteric testing business and boost profit margins raise optimism among investors on the stock.
Abbott Starts GUIDE-HF Clinical Trial for CardioMEMS Device
by Zacks Equity Research
Abbott (ABT) adopts ways to strengthen Heart Failure business under the Medical Device segment.
Trade War Fears Grip MedTech: 3 Stocks on the Line of Fire
by Urmimala Biswas
Chances of a retaliation from China leads to widespread losses in the medical device sector.
Edwards (EW) Completes Enrollment for PARTNER 3 Sub-Study
by Zacks Equity Research
Edwards' (EW) near-term product pipeline looks quite encouraging.
Baxter (BAX) Closes Acquisition of RECOTHROM & PREVELEAK
by Zacks Equity Research
Baxter (BAX) steadily focuses on improving its Advanced Surgery business.
Can Boston Scientific's Pain be a Boon for Edwards & Others?
by Sweta Jaiswal
Boston Scientific delaying the re-introduction of Lotus Valve devices provides an edge to its competitors in the highly lucrative TAVR market.
Abbott's MitraClip Therapy Wins Reimbursement Nod From MHLW
by Zacks Equity Research
Abbott (ABT) is is leaving no stone unturned to drive its Structural Heart business.
Goldman Sachs Backs Emerging Markets: MedTech Stocks in Focus
by Urmimala Biswas
According to Goldman Sachs, emerging markets are world's best investment in spite of several external hiccups. This comes as a breather for MedTech investors keen on exposure to emerging markets.
Diabetes Devices Market on a Tear: 3 Stocks for Solid Returns
by Sweta Jaiswal
Consider these three stocks in the rapidly-growing diabetes devices market for grand returns.
Is Big Pharma Using Corporate Tax Savings to Lower Drug Costs?
by Zacks Equity Research
Big pharma companies are using their savings in tax to boost shareholders' wealth through dividends or share buybacks, ignoring consumers.
Abbott Gets FDA Nod for Masters HP 15mm, Boosts Portfolio
by Zacks Equity Research
Abbott (ABT) adopts initiatives to strengthen the Structural Heart business within the Medical Device segment.
Zacks Industry Outlook Highlights: Abbott, Becton and Dickinson, Stryker, Varian Medical and Boston Scientific
by Zacks Equity Research
Zacks Industry Outlook Highlights: Abbott, Becton and Dickinson, Stryker, Varian Medical and Boston Scientific
Abbott to Strengthen Vascular Care Arm With Surmodics Deal
by Zacks Equity Research
Abbott (ABT) gains traction from its newly acquired rights over the SurVeil drug-coated balloon, which shows greater potential for capturing the market compared with traditional devices.
Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Covidien and Smith & Nephew, Abbott Labs and Boston Scientific
by Zacks Equity Research
Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Covidien and Smith & Nephew, Abbott Labs and Boston Scientific
Abbott (ABT) Down 6.7% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
FDA Grants Agios' (AGIO) Leukemia Candidate Priority Review
by Zacks Equity Research
FDA accepts Agios' NDA for its pipeline candidate ivosidenib (AG-120) and sets an action date of Aug 21, 2018.
Cardiovascular Systems Portfolio Solid, Competition Rife
by Zacks Equity Research
Cardiovascular Systems (CSII) expands product portfolio to enhance market reach.
Abbott's FreeStyle LibreLink App Now Available in Europe
by Zacks Equity Research
Abbott (ABT) leaves no stone unturned to cash in on the growing popularity of FreeStyle Libre system that eliminates the need for daily finger sticks.